Business
Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End
Salt Lake City, Utah--(Newsfile Corp. - November 9, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is providing a
About this update from Kiora Pharmaceuticals, Inc.
[{"type":"text","content":"Salt Lake City, Utah--(Newsfile Corp. - November 9, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (\"Kiora\" or the \"Company\") today is providing a business update and reporting financial results for the three and nine months ended September 30, 2022.\nManagement Discussion:\n\"We're advancing a diverse development pipeline of three differentiated assets across rare and narrowly-defined patient populations requiring new treatment options for ophthalmic disease,\" said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora.\n\"Following our recent capital raise, we are prioritizing our resources on developing KIO-301 as the first treatment that could potentially restore vision in patients with Retinitis Pigmentosa (RP). This strategy we believe provides the most cost-effective and time-efficient path to a substantive clinical milestone in an indication for which there are no approved drugs as well as a tremendous patient need. Our development team, led by Eric Daniels, M.D., has undertaken a significant effort to lay the foundation for the ABACUS clinical study, which has been approved to initiate enrollment and will imminently begin dosing the first of the planned six RP patients. Dr. Daniels and his team have dedicated their efforts to ensuring state-of-the-art testing and evaluation tools and protocols are in place to ensure we optimize the findings to inform the next stages of development.\n\"KIO-301 is a versatile compound with applications beyond a standalone treatment for RP. As a small molecule photoswitch, it has the potential to be used in combination with gene therapies currently in development to repair specific mutations associated with RP. In addition, it has the potential to address other inherited forms of blindness as well as age-related retinal degenerative diseases.\n\"Our development activities for KIO-201 are similarly focused on a rare ophthalmic indication, Persistent Corneal Epithelial Defects (PCED). This ocular surface condition is characterized by non-healing eye surface wounds. A small proof-of-concept study is currently underway to help inform our next steps. As a potential orphan indication, it offers us the pathway to cost-effectively bring a product to market with extended exclusivity.\n\"Our third product, KIO-101, addresses a non-orphan ophthalmic patient population, a subs...